Pesquisar
Vertex Pharmaceuticals Inc
VRTXAdicionar à lista de desejos
546.120USD
-11.840-2.12%
Fechamento 09-04 16:00（ET）
138.38BValor de mercado
32.12P/L TTM
Mais detalhes de Vertex Pharmaceuticals Inc Empresa
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Vertex Pharmaceuticals Inc Perfil
Código da empresaVRTX
Nome da EmpresaVertex Pharmaceuticals Inc
Data de listagemJul 24, 1991
CEOKewalramani (Reshma)
Número de funcionários6100
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 24
Endereço50 Northern Avenue
CidadeBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02210
Telefone16173416393
Sitehttps://www.vrtx.com/
Código da empresaVRTX
Data de listagemJul 24, 1991
CEOKewalramani (Reshma)
Executivos da empresa Vertex Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
35.24K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Perguntas frequentes
Quem são os cinco principais acionistas de Vertex Pharmaceuticals Inc?
Os cinco principais acionistas de Vertex Pharmaceuticals Inc são: Dr. Reshma Kewalramani, M.D.
Quantas instituições possuem ações da Vertex Pharmaceuticals Inc (VRTX)?
Em 2026Q1, 3075 instituições possuíam ações da Vertex Pharmaceuticals Inc, com valor de mercado aproximado de 247.47M, representando 97.50% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -4593876.00.
Qual é a maior fonte de receita da Vertex Pharmaceuticals Inc?
Em 2026Q1, o segmento de negócios TRIKAFTA gerou a maior receita para Vertex Pharmaceuticals Inc, totalizando 2.50B e representando 74.90% da receita total.